UTHR Quote, Financials, Valuation and Earnings

Geron has a net margin of 40.94% compared to United Therapeutics's net margin of -53.33%. United Therapeutics's return on equity of 20.21% beat Geron's return on equity of -59.29%.

United Therapeutics has a consensus price target of $400.54, signalling upside risk potential of 30.37%. On the other hand Geron has an analysts' consensus of $4.50 which suggests that it could grow by 174.39%. Given that Geron has higher upside potential than United Therapeutics, analysts believe Geron is more attractive than United Therapeutics.

United Therapeutics has a beta of 0.638, which suggesting that the stock is 36.156% less volatile than S&P 500. In comparison Geron has a beta of 0.535, suggesting its less volatile than the S&P 500 by 46.549%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $735.9M, which are larger than Geron quarterly revenues of $47.5M. United Therapeutics's net income of $301.3M is higher than Geron's net income of -$25.4M. Notably, United Therapeutics's price-to-earnings ratio is 12.49x while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 5.18x versus 13.76x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of 40.94% compared to United Therapeutics's net margin of -57.51%. United Therapeutics's return on equity of 20.21% beat Madrigal Pharmaceuticals's return on equity of -63.91%.

United Therapeutics has a consensus price target of $400.54, signalling upside risk potential of 30.37%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $401.67 which suggests that it could grow by 15.31%. Given that United Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe United Therapeutics is more attractive than Madrigal Pharmaceuticals.

United Therapeutics has a beta of 0.638, which suggesting that the stock is 36.156% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.403, suggesting its less volatile than the S&P 500 by 140.327%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $735.9M, which are larger than Madrigal Pharmaceuticals quarterly revenues of $103.3M. United Therapeutics's net income of $301.3M is higher than Madrigal Pharmaceuticals's net income of -$59.4M. Notably, United Therapeutics's price-to-earnings ratio is 12.49x while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 5.18x versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 40.94% compared to United Therapeutics's net margin of 2.31%. United Therapeutics's return on equity of 20.21% beat Pfizer's return on equity of 8.91%.

United Therapeutics has a consensus price target of $400.54, signalling upside risk potential of 30.37%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 21.76%. Given that United Therapeutics has higher upside potential than Pfizer, analysts believe United Therapeutics is more attractive than Pfizer.

United Therapeutics has a beta of 0.638, which suggesting that the stock is 36.156% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.57% to investors and pays a quarterly dividend of $0.43 per share. United Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

United Therapeutics quarterly revenues are $735.9M, which are smaller than Pfizer quarterly revenues of $17.8B. United Therapeutics's net income of $301.3M is lower than Pfizer's net income of $410M. Notably, United Therapeutics's price-to-earnings ratio is 12.49x while Pfizer's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 5.18x versus 2.30x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 40.94% compared to United Therapeutics's net margin of 24.22%. United Therapeutics's return on equity of 20.21% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

United Therapeutics has a consensus price target of $400.54, signalling upside risk potential of 30.37%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 38.42%. Given that Regeneron Pharmaceuticals has higher upside potential than United Therapeutics, analysts believe Regeneron Pharmaceuticals is more attractive than United Therapeutics.

United Therapeutics has a beta of 0.638, which suggesting that the stock is 36.156% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. United Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $735.9M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. United Therapeutics's net income of $301.3M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, United Therapeutics's price-to-earnings ratio is 12.49x while Regeneron Pharmaceuticals's PE ratio is 17.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 5.18x versus 5.40x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.